198 related articles for article (PubMed ID: 33784929)
1. Perspectives on the pharmacological management of psoriasis in pediatric and adolescent patients.
Mahé E; Amy De La Bretêque M; Phan C
Expert Rev Clin Pharmacol; 2021 Jul; 14(7):807-819. PubMed ID: 33784929
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation.
Potestio L; Tommasino N; Lauletta G; Feo F; Ruggiero A; Martora F; Portarapillo A; Guerriero L; Megna M
Expert Opin Drug Saf; 2024 Jun; 23(6):677-685. PubMed ID: 38699874
[TBL] [Abstract][Full Text] [Related]
3. Safety of current systemic therapies for nail psoriasis.
Hwang JK; Lipner SR
Expert Opin Drug Saf; 2023; 22(5):391-406. PubMed ID: 37329288
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients.
Eichinger JM; Shan DM; Greenzaid JD; Anakwenze L; Feldman SR
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):249-262. PubMed ID: 38529623
[TBL] [Abstract][Full Text] [Related]
5. Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond.
Portarapillo A; Potestio L; Tommasino N; Lauletta G; Feo F; Salsano A; Martora F; Caso F; Megna M
Expert Opin Pharmacother; 2024 Jun; ():. PubMed ID: 38916590
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapy for Pediatric Psoriasis.
Nogueira M; Paller AS; Torres T
Paediatr Drugs; 2021 May; 23(3):203-212. PubMed ID: 33811318
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.
Armstrong AW; Soliman AM; Betts KA; Wang Y; Gao Y; Puig L; Augustin M
Dermatol Ther (Heidelb); 2021 Jun; 11(3):885-905. PubMed ID: 33788177
[TBL] [Abstract][Full Text] [Related]
8. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
[TBL] [Abstract][Full Text] [Related]
9. Psoriasis.
Griffiths CEM; Armstrong AW; Gudjonsson JE; Barker JNWN
Lancet; 2021 Apr; 397(10281):1301-1315. PubMed ID: 33812489
[TBL] [Abstract][Full Text] [Related]
10. Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways.
Tollenaere MAX; Hebsgaard J; Ewald DA; Lovato P; Garcet S; Li X; Pilger SD; Tiirikainen ML; Bertelsen M; Krueger JG; Norsgaard H
Br J Dermatol; 2021 Sep; 185(3):585-594. PubMed ID: 33792895
[TBL] [Abstract][Full Text] [Related]
11. Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice.
Galíndez-Agirregoikoa E; Prieto-Peña D; Martín-Varillas JL; Joven B; Rusinovich O; Melero-González RB; Ortiz-Sanjuan F; Almodóvar R; Alegre-Sancho JJ; Martínez Á; Sellas-Fernández A; Méndez L; García-Vicuña R; Atienza-Mateo B; Gorostiza I; González-Gay MÁ; Blanco R;
J Rheumatol; 2021 Oct; 48(10):1552-1558. PubMed ID: 33795330
[TBL] [Abstract][Full Text] [Related]
12. Is apremilast for psoriasis as effective and safe as reported in clinical trials? Five-year experience from a Greek tertiary hospital: long-term real-life efficacy and safety of apremilast in Greece.
Sotiriou E; Tsentemeidou A; Vakirlis E; Sideris N; Bakirtzi K; Papadimitriou I; Lallas A; Ioannides D
Clin Exp Dermatol; 2021 Dec; 46(8):1542-1544. PubMed ID: 33811368
[TBL] [Abstract][Full Text] [Related]
13. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
14. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare.
Choon SE; Lebwohl MG; Marrakchi S; Burden AD; Tsai TF; Morita A; Navarini AA; Zheng M; Xu J; Turki H; Rajeswari S; Deng H; Tetzlaff K; Thoma C; Bachelez H
BMJ Open; 2021 Mar; 11(3):e043666. PubMed ID: 33785490
[TBL] [Abstract][Full Text] [Related]
15. Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review.
Thatiparthi A; Martin A; Liu J; Egeberg A; Wu JJ
Am J Clin Dermatol; 2021 Jul; 22(4):425-442. PubMed ID: 33861409
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week.
Garshick MS; Ward NL; Krueger JG; Berger JS
J Am Coll Cardiol; 2021 Apr; 77(13):1670-1680. PubMed ID: 33795041
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Psoriasis Area and Severity Index as a Proxy for Bio-markers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles.
Hoffmann JHO; Knoop C; Schäkel K; Enk AH; Hadaschik EN
Acta Derm Venereol; 2021 May; 101(5):adv00462. PubMed ID: 33903917
[TBL] [Abstract][Full Text] [Related]
18. Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis.
Lebwohl M; Soliman AM; Yang H; Wang J; Freimark J; Puig L
J Dermatolog Treat; 2022 Jun; 33(4):2094-2101. PubMed ID: 33899655
[TBL] [Abstract][Full Text] [Related]
19. Bimekizumab versus Secukinumab in Plaque Psoriasis.
Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results.
Umezawa Y; Asahina A; Imafuku S; Tada Y; Sano S; Morita A; Sakurai S; Hoshii N; Tilt N; Nakagawa H
Dermatol Ther (Heidelb); 2021 Jun; 11(3):943-960. PubMed ID: 33886085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
